Invitation: Conference Call on 25 August 2022, 10.00 a.m. CEST (9.00 a.m. BST)
presenting Marinomed`s H1 2022 results
Korneuburg, Austria, 12 August 2022 - Marinomed Biotech AG (VSE:MARI), Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics is pleased to invite you to an international conference call (held in English language) to present its H1 2022 results. The conference call is scheduled on 25 August 2022 for 10.00 a.m. CEST (9.00 a.m. BST). Your dialogue partners will be Dr. Andreas Grassauer, CEO, and Pascal Schmidt, CFO.
Pre-registration:
Participants may pre-register and will receive dedicated dial-in details to access the call easily and quickly:
The Marinomed presentation window will open at the beginning of the conference. The webcast does not support audio (please follow the instructions above for audio). The presentation can be downloaded c. 15 minutes before the conference call from the Company's website:
The press release on the H1 results 2022 will be published on 25 August 2022 at 7.45 a.m. CEST / 6.45 a.m. BST and will be available in the news section of the Company's website:
https://www.marinomed.com/en/news,
the report will be made available in the financial publications section:
If you have any further questions, please do not hesitate to contact: Stephanie Kniep, Investor Relations
Marinomed Biotech AG
Hovengasse 25, 2100 Korneuburg, Austria
E-Mail:ir@marinomed.com
T: +43 2262 90300 226
International Media Contact
MC Services AG
Dr. Brigitte Keller, Dr. Regina Lutz
T +49 89 210228 0
UK: Shaun Brown
M: +44 7867 515 918
E-Mail:marinomed@mc-services.eu
Disclaimer
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Marinomed Biotech AG published this content on 12 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 August 2022 07:35:02 UTC.
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.
MARINOMED BIOTECH AG 
